Huu Dat Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huu Dat Nguyen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Young Eun Kim
Department of Neurology Hallym University Sacred Heart Hospital, Hallym University Anyang Republic of Korea
9 shared publications Hyeo-Il Ma
Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University, Anyang, Gyeonggi, Republic of Korea; Laboratory of Parkinson's Disease and Neurodegenerative Disease, Hallym Institute for Translational Medicine, Anyang, Gyeonggi, Republic of Korea; Hallym Neurological Institute, Hallym University, Anyang, Gyeonggi, Republic of Korea
4 shared publicationsIn Hee Kwak
Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University, Anyang, Gyeonggi, Republic of Korea; Laboratory of Parkinson's Disease and Neurodegenerative Disease, Hallym Institute for Translational Medicine, Anyang, Gyeonggi, Republic of Korea; Department of Medical Sciences, Graduate School of Hallym University, Chuncheon, Gangwon, Republic of Korea
4 shared publications- Thanh Trung Nguyen
Department of Neurology Hallym University Sacred Heart Hospital, Hallym University Anyang Republic of Korea
4 shared publications - Hye Joung Choi
Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang-si, Republic of Korea
3 shared publications - Han-Joon Kim
Department of Neurology, Seoul National University Hospital, College of Medicine, Seoul National University, Seoul, Republic of Korea
2 shared publications
Latest Publications
- 21 September 2026
- Published by Wiley in Movement Disorders
Urine‐Derived Neuronal Extracellular Vesicle α ‐Synuclein Seed Amplification Assay for Synucleinopathies: A Non‐Invasive Biomarker Study
Background: α ‐Synuclein aggregation is a pathological hallmark of synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA). Although pathogenic α ‐synuclein seeds can be detected by real‐time quaking‐induced conversion (RT‐QuIC), current assays primarily rely on cerebrospinal fluid, whose invasiveness limits repeated and large‐scale applications. We therefore evaluated the feasibility of detecting pathogenic α ‐synuclein using urine‐derived neuronal extracellular vesicles (NEVs). Methods: Urine‐derived NEVs were enriched by direct immunoprecipitation using L1CAM‐conjugated magnetic beads. The RT‐QuIC assay was performed in 26 patients with PD, 13 with MSA, and 25 disease controls, including 16 healthy controls (HC), 4 with progressive supranuclear palsy (PSP), and 5 with normal pressure hydrocephalus (NPH). Results: Urine‐derived NEVs exhibited characteristic neuronal and exosomal markers and a typical extracellular vesicle size distribution. The urine‐based RT‐QuIC assay distinguished PD from disease controls with 73.1% sensitivity and 84% specificity, and MSA from disease controls with 76.9% sensitivity and 84% specificity. When compared with HC alone, sensitivity and specificity were 73.1% and 93.8% for PD, and 76.9% and 93.8% for MSA, respectively. Kinetic analysis showed higher maximum fluorescence intensity and area under the curve (AUC) in PD compared with both disease controls and HC ( P < 0.001 in all). MSA also demonstrated higher maximum fluorescence intensity than HC and increased AUC compared with both disease controls and HC ( P < 0.05 in all). Conclusions: We developed and optimized a completely non‐invasive urine‐derived NEV α ‐synuclein RT‐QuIC assay that demonstrates high specificity and moderate sensitivity for synucleinopathies. This approach warrants further validation in larger cohorts. © 2026 International Parkinson and Movement Disorder Society.
- 21 September 2026
- Published by Wiley in Movement Disorders
Urine‐Derived Neuronal Extracellular Vesicle α ‐Synuclein Seed Amplification Assay for Synucleinopathies: A Non‐Invasive Biomarker Study
Background: α ‐Synuclein aggregation is a pathological hallmark of synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA). Although pathogenic α ‐synuclein seeds can be detected by real‐time quaking‐induced conversion (RT‐QuIC), current assays primarily rely on cerebrospinal fluid, whose invasiveness limits repeated and large‐scale applications. We therefore evaluated the feasibility of detecting pathogenic α ‐synuclein using urine‐derived neuronal extracellular vesicles (NEVs). Methods: Urine‐derived NEVs were enriched by direct immunoprecipitation using L1CAM‐conjugated magnetic beads. The RT‐QuIC assay was performed in 26 patients with PD, 13 with MSA, and 25 disease controls, including 16 healthy controls (HC), 4 with progressive supranuclear palsy (PSP), and 5 with normal pressure hydrocephalus (NPH). Results: Urine‐derived NEVs exhibited characteristic neuronal and exosomal markers and a typical extracellular vesicle size distribution. The urine‐based RT‐QuIC assay distinguished PD from disease controls with 73.1% sensitivity and 84% specificity, and MSA from disease controls with 76.9% sensitivity and 84% specificity. When compared with HC alone, sensitivity and specificity were 73.1% and 93.8% for PD, and 76.9% and 93.8% for MSA, respectively. Kinetic analysis showed higher maximum fluorescence intensity and area under the curve (AUC) in PD compared with both disease controls and HC ( P < 0.001 in all). MSA also demonstrated higher maximum fluorescence intensity than HC and increased AUC compared with both disease controls and HC ( P < 0.05 in all). Conclusions: We developed and optimized a completely non‐invasive urine‐derived NEV α ‐synuclein RT‐QuIC assay that demonstrates high specificity and moderate sensitivity for synucleinopathies. This approach warrants further validation in larger cohorts. © 2026 International Parkinson and Movement Disorder Society.
- 11 August 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1383
TP53 status is associated with differential stress-marker expression and APP maturation in colon cancer cells
- 11 August 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1383
TP53 status is associated with differential stress-marker expression and APP maturation in colon cancer cells
- 29 July 2026
- Published by Wiley in Movement Disorders
Longitudinal Systemic Transcriptomic Profiling and Neuropathological Deposition of Neutrophil Extracellular Traps in Parkinson's Disease
Background: Altered immune responses including increased neutrophils have been reported in Parkinson's disease (PD); however, the role of neutrophil extracellular traps (NETs) remains unclear. Objective: The aim of this study was to evaluate the contribution of NETs to the systemic immunity and central nervous system (CNS) in PD pathogenesis. Methods: Transcriptomic analysis from the Parkinson's Progression Markers Initiative (PPMI) cohort was performed. Serum NETs were measured by myeloperoxidase (MPO)‐DNA and citrullinated histone H3 (CitH3)‐DNA complexes using enzyme‐linked immunosorbent assay (ELISA). In addition, NET structures in postmortem brains of individuals with PD and multiple system atrophy (MSA) were quantified using ELISA and visualized by confocal microscopy. Results: Differential expression gene analysis showed significant systemic upregulation of PADI4 expression, which encodes the NET‐priming enzyme peptidylarginine deiminase 4, in patients with PD compared with control subjects. In the regional cross‐sectional cohort, serum MPO‐DNA complexes were reduced in patients with PD compared with control subjects and showed a graded reduction with disease severity; this reduction was independently replicated using a CitH3‐DNA ELISA. In contrast, NET structures were markedly increased in postmortem brain tissues from individuals with PD and MSA compared with control subjects. Confocal imaging further confirmed the presence of NETs in the PD brain cortex, with an increased density in the substantia nigra and in close proximity to Lewy bodies. Conclusions: These findings demonstrated systemic priming of NET‐associated pathways accompanied by reduced circulating NET complexes in PD, alongside substantial NETs deposition within the CNS. Together, these observations identify the PADI4‐NET axis as a candidate immune feature of PD that warrants further mechanistic investigation. © 2026 International Parkinson and Movement Disorder Society.
- 29 July 2026
- Published by Wiley in Movement Disorders
Longitudinal Systemic Transcriptomic Profiling and Neuropathological Deposition of Neutrophil Extracellular Traps in Parkinson's Disease
Background: Altered immune responses including increased neutrophils have been reported in Parkinson's disease (PD); however, the role of neutrophil extracellular traps (NETs) remains unclear. Objective: The aim of this study was to evaluate the contribution of NETs to the systemic immunity and central nervous system (CNS) in PD pathogenesis. Methods: Transcriptomic analysis from the Parkinson's Progression Markers Initiative (PPMI) cohort was performed. Serum NETs were measured by myeloperoxidase (MPO)‐DNA and citrullinated histone H3 (CitH3)‐DNA complexes using enzyme‐linked immunosorbent assay (ELISA). In addition, NET structures in postmortem brains of individuals with PD and multiple system atrophy (MSA) were quantified using ELISA and visualized by confocal microscopy. Results: Differential expression gene analysis showed significant systemic upregulation of PADI4 expression, which encodes the NET‐priming enzyme peptidylarginine deiminase 4, in patients with PD compared with control subjects. In the regional cross‐sectional cohort, serum MPO‐DNA complexes were reduced in patients with PD compared with control subjects and showed a graded reduction with disease severity; this reduction was independently replicated using a CitH3‐DNA ELISA. In contrast, NET structures were markedly increased in postmortem brain tissues from individuals with PD and MSA compared with control subjects. Confocal imaging further confirmed the presence of NETs in the PD brain cortex, with an increased density in the substantia nigra and in close proximity to Lewy bodies. Conclusions: These findings demonstrated systemic priming of NET‐associated pathways accompanied by reduced circulating NET complexes in PD, alongside substantial NETs deposition within the CNS. Together, these observations identify the PADI4‐NET axis as a candidate immune feature of PD that warrants further mechanistic investigation. © 2026 International Parkinson and Movement Disorder Society.
- Open Access
- 13 February 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
CREB2 Functions as a Central Mediator of Oxidative Neuronal Death Triggered by Microglial Glutamate Release Under Neuroinflammatory Conditions
Glutamate-induced oxidative cytotoxicity is a major driver of neuronal loss in neurodegenerative diseases, yet the upstream transcriptional regulators linking oxidative stress to neuronal death remain unclear despite the known involvement of the p53–GADD45α pathway. CREB2 (ATF4) is a stress-responsive transcription factor, but its role in microglia-mediated oxidative neurotoxicity has not been fully defined. Here, we investigated CREB2 function in oxidative glutamate toxicity using HT22 hippocampal neurons, primary mouse hippocampal cells, and a kainic acid (KA)-injected rat model. Oxidative stress was induced by glutamate, intracellular ROS levels were quantified with DCFDA, and the antioxidant N-acetylcysteine (NAC) was used to confirm oxidative dependency. Microglia-derived glutamate was assessed by stimulating BV2 cells with lipopolysaccharide (LPS) and applying glutamate-containing conditioned medium (LPS-CM) to HT22 cells. Exogenous glutamate robustly increased CREB2 expression in HT22 and primary neurons, accompanied by ROS accumulation and cell death, whereas NAC suppressed these effects. Inhibition of p53 by siRNA or pifithrin-α (PFT-α) attenuated glutamate-induced CREB2 upregulation, and CREB2 knockdown blocked GADD45α induction and protected neurons. In Vivo, KA injection caused robust CREB2 upregulation in the damaged CA3 region. Importantly, conditioned medium from LPS-activated BV2 microglia increased CREB2 expression and ROS levels in HT22 cells in an NAC-sensitive manner, supporting a glutamate-associated oxidative mechanism rather than receptor-mediated excitotoxicity. Collectively, these results suggest that CREB2 functions between upstream p53 signaling and downstream GADD45α activation as a redox-sensitive mediator of oxidative neuronal death, and may represent a potential therapeutic target in neurodegenerative diseases associated with oxidative stress and neuroinflammation.
- 13 February 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Open AccessCREB2 Functions as a Central Mediator of Oxidative Neuronal Death Triggered by Microglial Glutamate Release Under Neuroinflammatory Conditions
Glutamate-induced oxidative cytotoxicity is a major driver of neuronal loss in neurodegenerative diseases, yet the upstream transcriptional regulators linking oxidative stress to neuronal death remain unclear despite the known involvement of the p53–GADD45α pathway. CREB2 (ATF4) is a stress-responsive transcription factor, but its role in microglia-mediated oxidative neurotoxicity has not been fully defined. Here, we investigated CREB2 function in oxidative glutamate toxicity using HT22 hippocampal neurons, primary mouse hippocampal cells, and a kainic acid (KA)-injected rat model. Oxidative stress was induced by glutamate, intracellular ROS levels were quantified with DCFDA, and the antioxidant N-acetylcysteine (NAC) was used to confirm oxidative dependency. Microglia-derived glutamate was assessed by stimulating BV2 cells with lipopolysaccharide (LPS) and applying glutamate-containing conditioned medium (LPS-CM) to HT22 cells. Exogenous glutamate robustly increased CREB2 expression in HT22 and primary neurons, accompanied by ROS accumulation and cell death, whereas NAC suppressed these effects. Inhibition of p53 by siRNA or pifithrin-α (PFT-α) attenuated glutamate-induced CREB2 upregulation, and CREB2 knockdown blocked GADD45α induction and protected neurons. In Vivo, KA injection caused robust CREB2 upregulation in the damaged CA3 region. Importantly, conditioned medium from LPS-activated BV2 microglia increased CREB2 expression and ROS levels in HT22 cells in an NAC-sensitive manner, supporting a glutamate-associated oxidative mechanism rather than receptor-mediated excitotoxicity. Collectively, these results suggest that CREB2 functions between upstream p53 signaling and downstream GADD45α activation as a redox-sensitive mediator of oxidative neuronal death, and may represent a potential therapeutic target in neurodegenerative diseases associated with oxidative stress and neuroinflammation.
- Open Access
- 31 January 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (1) , 31-38
Differential Peripheral NLRP3 Inflammasome Expression in Patients With Parkinson’s Disease and Patients With Multiple System Atrophy
Objective The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has been proposed to be a downstream mediator of neuroinflammation in individuals with Parkinson’s disease (PD). However, its involvement across disease stages and related synucleinopathies, such as multiple system atrophy (MSA), remains unclear. We aimed to analyze the peripheral mRNA expression of NLRP3-related genes and cytokines across individuals with isolated REM sleep behavior disorder (iRBD), early-stage PD, late-stage PD, and MSA.Methods Peripheral blood mononuclear cells (PBMCs) were collected from 151 participants: 35 healthy controls (HCs), 31 patients with iRBD, 41 patients with early-stage PD, 21 patients with late-stage PD, and 23 patients with MSA. mRNA expression was measured using quantitative real-time polymerase chain reaction. Statistical comparisons were performed using analysis of variance (ANOVA) or Welch’s ANOVA, and associations with clinical variables were analyzed through stepwise multiple linear regression.Results NLRP3 expression was significantly lower in patients with iRBD (p=0.0263) and patients with early-stage PD (p= 0.0101) than in HCs. NIMA-related kinase 7 (NEK7) expression progressively decreased across the disease spectrum (HCs vs. patients with early-stage PD, p=0.0008; vs. patients with late-stage PD, p<0.0001). In contrast, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and caspase-1 were elevated in patients with PD, especially those in the late stages. Levels of patients with MSA resembled those of HCs but differed from those of patients with PD. Interleukin (IL)-1β and IL-18 levels were not significantly different. In patients with early-stage PD, NLRP3 expression was negatively correlated with disease duration, the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part II score, and the cognitive score.Conclusion Our findings challenge the prevailing hypothesis that NLRP3 inflammasome activation directly contributes to PD pathogenesis. Instead, the observed increase in ASC and caspase-1 expression suggests the potential involvement of alternative inflammasome pathways during disease progression.
- 31 January 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (1) , 31-38
Open AccessDifferential Peripheral NLRP3 Inflammasome Expression in Patients With Parkinson’s Disease and Patients With Multiple System Atrophy
Objective The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has been proposed to be a downstream mediator of neuroinflammation in individuals with Parkinson’s disease (PD). However, its involvement across disease stages and related synucleinopathies, such as multiple system atrophy (MSA), remains unclear. We aimed to analyze the peripheral mRNA expression of NLRP3-related genes and cytokines across individuals with isolated REM sleep behavior disorder (iRBD), early-stage PD, late-stage PD, and MSA.Methods Peripheral blood mononuclear cells (PBMCs) were collected from 151 participants: 35 healthy controls (HCs), 31 patients with iRBD, 41 patients with early-stage PD, 21 patients with late-stage PD, and 23 patients with MSA. mRNA expression was measured using quantitative real-time polymerase chain reaction. Statistical comparisons were performed using analysis of variance (ANOVA) or Welch’s ANOVA, and associations with clinical variables were analyzed through stepwise multiple linear regression.Results NLRP3 expression was significantly lower in patients with iRBD (p=0.0263) and patients with early-stage PD (p= 0.0101) than in HCs. NIMA-related kinase 7 (NEK7) expression progressively decreased across the disease spectrum (HCs vs. patients with early-stage PD, p=0.0008; vs. patients with late-stage PD, p<0.0001). In contrast, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and caspase-1 were elevated in patients with PD, especially those in the late stages. Levels of patients with MSA resembled those of HCs but differed from those of patients with PD. Interleukin (IL)-1β and IL-18 levels were not significantly different. In patients with early-stage PD, NLRP3 expression was negatively correlated with disease duration, the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part II score, and the cognitive score.Conclusion Our findings challenge the prevailing hypothesis that NLRP3 inflammasome activation directly contributes to PD pathogenesis. Instead, the observed increase in ASC and caspase-1 expression suggests the potential involvement of alternative inflammasome pathways during disease progression.
- Open Access
- 30 October 2025
- Published by Elsevier in EBioMedicine
- Vol. 121, 105990
Pathological role of immunoproteasome PSMB8 in Parkinson's disease: a link between α-synuclein aggregation and immune activation
- 30 October 2025
- Published by Elsevier in EBioMedicine
- Vol. 121, 105990
Open AccessPathological role of immunoproteasome PSMB8 in Parkinson's disease: a link between α-synuclein aggregation and immune activation
- 8 May 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 136, 107857
Prevalence and clinical impact of alpha-synuclein pathology in idiopathic normal pressure hydrocephalus: Insights from RT-QuIC assay
- 8 May 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 136, 107857
Prevalence and clinical impact of alpha-synuclein pathology in idiopathic normal pressure hydrocephalus: Insights from RT-QuIC assay
- 4 August 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 114, 105797
Upregulation of immunoproteasome PSMB8 is associated with Parkinson’s disease
- 4 August 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 114, 105797
Upregulation of immunoproteasome PSMB8 is associated with Parkinson’s disease
- Open Access
- 7 October 2022
- Published by Springer Nature in Research Square
Alteration of immunoproteasome mRNA in PBMCs of patients with Parkinson’s disease
Background Immunoproteasome, a part of ubiquitin–proteasome system, is involved in protein degradation and immune response. However, the relationship between immunoproteasome and Parkinson’s disease (PD) was not evaluated clearly. We hypothesized that the shift of immunoproteasome attributes to PD due to its role in immune system and protein homeostasis. Objective To determine whether immunoproteasome mRNA in peripheral blood mononuclear cells is expressed differently between patients with PD and healthy controls and to test its value as a biomarker of PD Methods Blood samples were collected from 19 healthy controls and 40 patients with PD of comparable ages. Peripheral blood mononuclear cells were isolated and used to measure by RT-qPCR the mRNA levels of three catalytic subunits of immunoproteasome, namely, PSMB8, PSMB9, and PSMB10. Results The levels PSMB9 and PSMB10 mRNA were not different between the PD group and healthy control group, whereas the PSMB8 mRNA in PD group significantly increased. The ratio of PSMB10 and PSMB8 (PSMB10/8) best reflected significant difference between the PD group and healthy control group (p = 0.002). This ratio can discriminate all PD, mild PD (Hoehn and Yahr ≤ 2.5), and drug-naive PD from healthy controls. We found correlation between the PSMB10/8 ratio with the UPDRS total and Part III score in the mild PD subgroup and drug-naive PD subgroups Conclusion The expression of PSMB8 mRNA increased in PD, and the PSMB10/8 ratio can differentiate Parkinson’s disease from healthy controls.
- 7 October 2022
- Published by Springer Nature in Research Square
Open AccessAlteration of immunoproteasome mRNA in PBMCs of patients with Parkinson’s disease
Background Immunoproteasome, a part of ubiquitin–proteasome system, is involved in protein degradation and immune response. However, the relationship between immunoproteasome and Parkinson’s disease (PD) was not evaluated clearly. We hypothesized that the shift of immunoproteasome attributes to PD due to its role in immune system and protein homeostasis. Objective To determine whether immunoproteasome mRNA in peripheral blood mononuclear cells is expressed differently between patients with PD and healthy controls and to test its value as a biomarker of PD Methods Blood samples were collected from 19 healthy controls and 40 patients with PD of comparable ages. Peripheral blood mononuclear cells were isolated and used to measure by RT-qPCR the mRNA levels of three catalytic subunits of immunoproteasome, namely, PSMB8, PSMB9, and PSMB10. Results The levels PSMB9 and PSMB10 mRNA were not different between the PD group and healthy control group, whereas the PSMB8 mRNA in PD group significantly increased. The ratio of PSMB10 and PSMB8 (PSMB10/8) best reflected significant difference between the PD group and healthy control group (p = 0.002). This ratio can discriminate all PD, mild PD (Hoehn and Yahr ≤ 2.5), and drug-naive PD from healthy controls. We found correlation between the PSMB10/8 ratio with the UPDRS total and Part III score in the mild PD subgroup and drug-naive PD subgroups Conclusion The expression of PSMB8 mRNA increased in PD, and the PSMB10/8 ratio can differentiate Parkinson’s disease from healthy controls.